Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 123

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 123
---
 estimates that the accessible market for Arakoda represents about one third of this volume (about 330,000 prescriptions). Barriers to entry include low brand awareness in the prescriber community and the low cost of some of the generic alternatives. In the second half of 2024 we will conduct a pilot commercialization study to confirm these barriers can be overcome (see “Strategy”). 74 Treatment and Prevention of Tick-Borne Disease (Babesiosis) We are repositioning the Arakoda regimen of Tafenoquine for several potential new therapeutic indications that have substantial U.S. caseloads, as further described below:

| ● | Treatment                                                                                                                              
 of Chronic Tick-Borne Disease (Babesiosis). Babesia parasites are co-transmitted by the same ticks that transmit Borrelia,             
 the Lyme disease bacterium. Although Lyme in the acute phase is generally viewed by the medical community as being treatable with      
 antibiotics, individuals who are not treated, or fail treatment, may go on to develop long term, and potentially debilitating, chronic 
 symptoms such as fatigue, body aches, and cognitive problems.41 This condition is defined by the Centers for Disease Control           
 and Prevention (“CDC”) as Post-Treatment Lyme Disease Syndrome (“PTLDS”) or simply as Lyme in the patient                              
 community.1 Although there are no published estimates, key opinion leaders have stated that as many as 50% of Lyme/PTLDS               
 patients are believed to be co-infected with Babesia parasites, a diagnosis referred to in the Lyme community as “Chronic              
 Babesiosis.” Prescribers in the Lyme disease community utilize a number of therapeutic modalities to manage the symptoms of            
 Chronic Babesiosis, including FDA-approved pharmaceuticals such as atovaquone and azithromycin (these are assumed to suppress the      
 growth of Babesia parasites).42                                                                                                        |

Recent market data shows that Tafenoquine appears to be increasingly prescribed by Lyme physicians to manage Chronic Babesiosis. This trend may follow the recent publication of several case reports demonstrating activity in immunosuppressed patients with acute babesiosis, and animal data showing eradication of Babesiaparasites with Tafenoquine (primarily as Arakoda). 44The Company believes the recent increases in sales of Arakoda have been driven by organic growth of these activities. There are no formal epidemiological publications articulating the incidence or prevalence of Chronic Babesiosis, so these metrics must be inferred based